Cognitive Improvement Effect of Resplex Alpha A in the Scopolamine-induced Mouse Model
CELLMED / CELLMED, (P)3022-6805; (E)3022-6791
2023, v.13 no.14, pp.1-1
https://doi.org/10.5667/CellMed.2023.014
Bong-Keun Jang (JBK-LAB, Inc.)
Youngsun Kwon (JBK-LAB, Inc.)
Sunyoung Park (JBK-LAB, Inc.)
Gunwoo Lee (JBK-LAB, Inc.)
Hye-yeon Kang (JBK-LAB, Inc.)
Jeom-Yong Kim (JBK-LAB, Inc.)
Bong-Keun,
J.
, Youngsun,
K.
, Sunyoung,
P.
, Gunwoo,
L.
, Hye-yeon,
K.
, &
Jeom-Yong,
K.
(2023). Cognitive Improvement Effect of Resplex Alpha A in the Scopolamine-induced Mouse Model. CELLMED, 13(14), 1-1, https://doi.org/10.5667/CellMed.2023.014
Abstract
Administration of Scopolamine can be considered a psychopharmacological model of Alzheimer's disease (AD). We made an animal model of Alzheimer's disease (AD) by administering Scopolamine to Blab/c mice. In this study, we investigated the effects of Resplex Alpha on memory impairment and cognitive function in mice in a mouse animal model of Scopolamine-induced memory impairment. Through Y-mazed and passive avoidance behavioral assays, we observed that Resplex Alpha recovered Scopolamine-induced short-term memory and cognitive functions. The results of our study imply that Resplex Alpha may be beneficial in the prevention of Alzheimer's disease (AD).
- keywords
-
Resveratrol-alginate nano-complex (RANCP),
Ginkgo biloba extract (EGb231),
Cognitive function,
Memory dysfunction,
Alzheimer’s disease (AD),
dementia